NRIX vs. PRAX, CMPS, PMVP, LGND, ARVN, XENE, FOLD, ARWR, PTCT, and MOR
Should you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include Praxis Precision Medicines (PRAX), COMPASS Pathways (CMPS), PMV Pharmaceuticals (PMVP), Ligand Pharmaceuticals (LGND), Arvinas (ARVN), Xenon Pharmaceuticals (XENE), Amicus Therapeutics (FOLD), Arrowhead Pharmaceuticals (ARWR), PTC Therapeutics (PTCT), and MorphoSys (MOR). These companies are all part of the "pharmaceutical preparations" industry.
Praxis Precision Medicines (NASDAQ:PRAX) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings.
Praxis Precision Medicines has a beta of 2.87, meaning that its share price is 187% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.
Praxis Precision Medicines has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.
67.8% of Praxis Precision Medicines shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 7.2% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Nurix Therapeutics has a net margin of -178.93% compared to Nurix Therapeutics' net margin of -5,711.85%. Praxis Precision Medicines' return on equity of -67.08% beat Nurix Therapeutics' return on equity.
Praxis Precision Medicines currently has a consensus target price of $105.80, indicating a potential upside of 122.92%. Nurix Therapeutics has a consensus target price of $21.88, indicating a potential upside of 38.89%. Given Nurix Therapeutics' higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Nurix Therapeutics.
In the previous week, Nurix Therapeutics had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 6 mentions for Nurix Therapeutics and 1 mentions for Praxis Precision Medicines. Nurix Therapeutics' average media sentiment score of 1.26 beat Praxis Precision Medicines' score of 0.75 indicating that Praxis Precision Medicines is being referred to more favorably in the media.
Nurix Therapeutics received 24 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. Likewise, 71.43% of users gave Nurix Therapeutics an outperform vote while only 63.41% of users gave Praxis Precision Medicines an outperform vote.
Summary
Nurix Therapeutics beats Praxis Precision Medicines on 11 of the 18 factors compared between the two stocks.
Get Nurix Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nurix Therapeutics Competitors List
Related Companies and Tools
